Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Keytruda Qlex by Quarter
Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous, launched Q3 2025) — U.S. sales ($M) ($M)
Merck Keytruda Qlex: $395M in Q2 2026.
Latest, Q2 2026
395
Period ended Jun 30, 2026
Change on a year earlier
–
0 in Q2 2025
History
4 quarters
Since Q1 2025
Sources
2
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-07) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph subcutaneous, launched Q3 2025) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 395 | – | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 106 | – | Form 10-Q (filed 2026-05-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 0 | – | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 0 | – | Form 10-Q (filed 2026-05-04) ↗ |
Cite this data
StockData. (2026). Merck Keytruda Qlex ($M), quarterly Q1 2025–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-keytruda-qlex-us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.